Health Care Supplies

Endovastec

Endovastec released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 370.24 M, actual EPS CNY 1.28

Endovastec to Release FY2026 Q1 Earnings on April 30 After-Market BJT

Endovastec to release FY2025 earnings report on March 31 during market hours (BJT), forecast revenue CNY 1.537 B, EPS CNY 5.0297

Endovastec released FY2025 earnings on February 27 During-Market (BJT), actual revenue CNY 1.351 B (forecast CNY 1.537 B), actual EPS CNY 4.65 (forecast CNY 5.0297)

Endovastec released FY2025 Q4 earnings on February 27 During-Market (BJT), actual revenue CNY 335.85 M, actual EPS CNY 1.1099

Endovastec released FY2025 9 Months earnings on October 29 After-Market (BJT), actual revenue CNY 1.015 B, actual EPS CNY 3.5295

Endovastec released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 300.35 M, actual EPS CNY 0.9793

Endovastec to Release FY2025 Q3 Earnings on October 30 After-Market BJT

Endovastec released FY2025 Q2 earnings on August 26 After-Market BJT, actual revenue CNY 382.24 M, actual EPS CNY 1.5002

Endovastec released FY2025 Semi-Annual Earnings on August 26 After-Market (BJT), with actual revenue of CNY 714.43 M and EPS of CNY 2.55

Endovastec to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Zhongyou Securities Gives Buy Rating to Shimayi Medical

Mindu Medical Expected to See 2025 H1 Net Profit Decrease YoY

Shentech Medical Obtains BBB ESG Rating

GF Securities Maintains Buy Rating on Shimayi Medical

Shimay Medical Reports Decline in Revenue and Net Profit for Q1 2025

Endovastec released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 332.19 M, actual EPS CNY 1.05

Endovastec FY2025 Q1 Earnings Release on April 30 After-Market BJT

Heartbeat Medical's 2024 Performance Plummets Due to Price Issues Raised by Medical Insurance Bureau

Xinmai Medical Releases 2024 Performance Report, Accelerates International Business Expansion

00853

688016

MicroPort Scientific reported 2025 sales of US$994.91 million and net income of US$48.52 million. The company announced a leadership change, with Dr. Zhaohua Chang stepping down as CEO and Jonathan W. Chen taking over as rotating CEO. This leadership refresh aims to align operational decisions with global expansion goals. While the return to profitability is promising, the new structure introduces execution risks. Analysts suggest the stock may be trading above fair value, indicating potential downside despite a positive investment narrative.

Simplywall

MICROPORT

What MicroPort Scientific (SEHK:853)'s Profit Return and Rotating CEO Overhaul Means For Shareholders

02160

688351

02172

02252

159883

562600

159898

Bank of America Securities has lowered the target price for MICROPORT to 13.9 yuan, reiterating a "Buy" rating. It expects total revenue in 2025 to be USD 1.105 billion, with a year-on-year increase of 6% after excluding foreign exchange factors. Its "GloMatrix" platform has achieved breakeven, and revenue for the fiscal year 2025 is expected to grow by 78.8% to 163.9 million yuan. Due to the exclusion of MICROPORT NEURO from the consolidated financial statements, revenue forecasts for 2026 to 2028 have been reduced by 10.9% to 12.9%. At the same time, gross margin forecasts have been raised by 1.9 to 2.1 percentage points, and operating expense ratio forecasts have been raised by 11.5 to 12.6 percentage points

AASTOCKS

MP CARDIOFLOW-B

MICROPORT EP

MICROPORT NEURO

MircroPort Medbot-B

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

44005

40168

MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles

Tip Ranks

MICROPORT POF-D

First Trust NYSE Arca Biotech Index Fd

MICROPORT B2812

MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles

Shares of MicroPort Endovascular MedTech Group surged 10.2% to CNY111.80 after the US FDA granted Breakthrough Device Designation to its innovative stent graft system, expediting market approval. The Hector Multi-Branch Thoracic Aortic Stent Graft System aims for minimally invasive treatment of thoracic aortic lesions. MicroPort reported a 12% rise in net profit to CNY563 million last year, driven by innovative product launches and a 55% increase in overseas sales. The device has received EU certification and is in clinical trials in China, addressing high-risk aortic arch lesions with less invasive methods.

Yicai

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

MICROPORT announced that its 40.32% subsidiary Endovastec achieved revenue of RMB 1.351 billion for the fiscal year 2025, an increase of 12% year-on-year. The net profit attributable to shareholders was RMB 563 million, a growth of 12.2%

MicroPort earned 563 million RMB last year, an increase of 12.2%

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

Endovastec(688016.SH)

What MicroPort Scientific (SEHK:853)'s Profit Return and Rotating CEO Overhaul Means For Shareholders

Bank of America Securities lowers the target price for MicroPort to 13.9 yuan, reiterating a "Buy" rating

MicroPort Sets Up Global Executive Committee and Reshapes Top Management Roles

China's MicroPort Soars After US Grants Its New Stent Breakthrough Device Status

MicroPort earned 563 million RMB last year, an increase of 12.2%

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year